Published : 28 Aug 2020
Aagami has succeeded in establishing a partnership for its Australian client which has a proven technology for producing high value(multi-billion dollar) products from algae.
An India based large global pharma has signed a term sheet with a Biotech client of Aagami for an investment of AU$22 Million with a potential for further funding culminating in to acquisition.
Earlier in March 2020, intense in-person meetings were done involving Aagami CEO, VP, Aagami Client CEO, and Chief of the large Pharma, and his entire Finance, Strategy, Operations and Technical team.
A definitive agreement is expected to be signed soon.
While we pray for safety and good health of all, Aagami are proud to have made this deal happen, despite the Covid-19 slowdown. It has been our pleasure to help our client reach their goals. After all, ‘the Client success is our success’.